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ABSTRACT
The underlying mechanism of cell injury during ischemia and reperfusion is complex and timesesnsitive. Some processess 
develop coincidentally with the onset of ischemia and during reperfusion leading to abnormalities in energy metabolism, 
acid base status, and intracellular ion homeostasis. Other processes develop later and encompass activation of various 
signalling pathways that have deleterious or beneficial effects on specific effectors, but associated with sustained 
disruption of energy production contractile dysfunction and activation of apoptotic pathways. Discussion on the various 
cell mechanisms resposible for cell injury is beyond the scope of this review. However, pertinent to our discussion is the 
mounting evidence pointing to mitochondria as key target organelles of reperfusion injury.
RAÚL J. GAZMURI (  ), 
IYAD M. AYOUB, 
JEEJABAI RADHAKRISHNAN
Rosalind Franklin University 
of Medicine and Science





RAÚL J. GAZMURI • IYAD M. AYOUB • JEEJABAI RADHAKRISHNAN
REVIEW
   SIGNA VITAE 2008; 3(1): 7 - 12
Key words: cardiac arrest, mito-
chondrial injury, cardiopulmonary 
resuscitation, apoptosis
The working heart is a highly meta-
bolically active organ that consumes 
close to 10% of the total body oxygen 
consumption. It extracts nearly 70% 
of the oxygen supplied by the coro-
nary circuit but has little capability for 
extracting additional oxygen. Accord-
ingly, increased metabolic demands 
are met through coronary vasodilation 
resulting in increased blood flow and 
oxygen delivery. (1,2) As a result, a 
severe energy imbalance develops dur-
ing cardiac arrest shortly after coronary 
blood flow ceases. The severity of the 
energy deficit is contingent on the met-
abolic requirements and is particularly 
high when ventricular fibrillation (VF) 
is present; because the energy needs 
of the fibrillating heart are the same or 
more than the normally beating heart. 
(3) A lesser energy requirement occurs 
when cardiac arrest occurs in the qui-
escent or minimally active heart (i.e., 
asystole or pulseless electrical activity 
as a result of asphyxia or exsanguina-
tions). (4) However, most experimental 
studies have examined the myocardial 
manifestations of cardiac arrest and 
resuscitation in animal models of VF.
After cessation of coronary blood flow 
and oxygen delivery, the mitochondrial 
capability for ATP regenerating through 
oxidative phosphorylation stops prompt-
ing anaerobic regeneration of limited 
amount of ATP at the substrate level 
from breakdown of creatine phosphate 
and oxidation of pyruvate to lactate. (5-
7) This leads to rapid depletion of cre-
atine phosphate, marked elevation in 
lactate, and a relatively slow depletion 
of ATP. (6) We observed in a rat model 
of VF, that 10 minutes of untreated VF 
were accompanied by decreases in 
myocardial creatine phosphate and 
ATP to levels corresponding to 7% and 
19% of baseline, respectively, whereas 
the lactate content increased by more 
than 50-fold. (8) Along with the energy 
deficit, ischemia is accompanied by 
accumulation of CO2 and H+ yield-
ing profound myocardial acidosis. (9) 
Acidosis, however, is believed to be 
protective. Several studies have shown 
that hypoxic cells and tissues are pre-
served better in an acidic environment. 
(10-12)
Conventional closed-chest resuscita-
tion is hemodynamically limited failing to 
generate a coronary blood flow greater 
than 20% of normal. (13) Such low flow 
fails to reverse myocardial ischemia but 
is sufficient to activate multiple patho-
genic mechanisms triggering what is 
known as reperfusion injury. Accord-
ingly, resuscitation typically proceeds 
during and in spite of severe myocardial 
ischemia and in the midst of reperfusion 
injury compounded by specific resus-
citation interventions which can also 
injure the myocardium, such as electri-
cal shocks and adrenergic vasopressor 
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agents. The end result is that several 
functional myocardial abnormalities 
develop during cardiac resuscitation 
which may compromise resuscitability 
and survival. These myocardial abnor-
malities can be grouped into those that 
manifest during the resuscitation effort 
and those that manifest after return of 
spontaneous circulation. The former 
include decreased left ventricular com-
pliance and increased resistance to 
electrical defibrillation; the latter include 
reperfusion arrhythmias and myocar-
dial dysfunction.
Decreased left ventricular 
compliance
A progressive reduction in left ventricu-
lar compliance characterized by reduc-
tions in cavity size and wall thickening 
but without changes in cavity pressure 
has been documented by our group 
and others during closed-chest resusci-
tation. (14-17) A comparable phenom-
enon has been reported in humans dur-
ing open-chest direct cardiac compres-
sion. (18) Decreases in left ventricular 
compliance can compromise preload-
dependent blood flow generation and 
partly explain time-dependent reduc-
tions in the hemodynamic efficacy of 
closed-chest resuscitation. (16,17)  We 
have reported that this phenomenon 
can be prevented by administration 
of inhibitors of the sodium-hydrogen 
exchanger isoform-1 (NHE-1), enabling 
in closed-chest models to prolong the 
duration of hemodynamically effective 
chest compression. (16,17)
We have prev iously interpreted 
decreases in left ventricular compli-
ance as a manifestation of ischemic 
contracture. (3,16) However, ischemic 
contracture is characteristically pre-
ceded by reductions in myocardial ATP 
to less than 10% of normal, (19) and 
typically occurring after long intervals of 
no-flow ischemia. In recent studies we 
have reported decreases in ventricular 
compliance with myocardial ATP levels 
of ≈ 55% of baseline and prevention 
by the NHE-1 inhibitor zoniporide. (20) 
This would suggest that reperfusion 
leading to Na+-induced cytosolic Ca2+ 
overload may play a critical role. How-
ever, delayed reversal of intracellular 
acidosis by NHE-1 inhibition at the time 
of reperfusion may also contribute to 
preserve compliance. (21)
Resistance to defibrillation
Electrical shocks delivered immediately 
after onset of VF are consistently effec-
tive in terminating VF and reestablishing 
mechanical cardiac activity. Even short 
delays (i.e. up to 3 minutes) may not 
be substantially detrimental resulting in 
more than 50% likelihood of success-
ful resuscitation. (22) However, longer 
intervals of untreated VF, as character-
istically occurs in out-of-hospital set-
tings, are associated with decreased 
effectiveness of defibrillation attempts. 
Under these conditions electrical 
shocks typically fail to terminate VF, 
or terminate VF precipitating asystole 
or a pulseless electrical activity. (23) 
Additional resuscitation interventions 
are required to restore myocardial con-
ditions favorable to successful defi-
brillation. New approaches are being 
developed to optimize the effectiveness 
of electrical defibrillation by identifying 
the proper timing for shock delivery 
and by using safer and more effective 
defibrillation waveforms. (24,25)
Reperfusion arrhythmias
Electrical instability manifested by pre-
mature ventricular complexes and epi-
sodes of ventricular tachycardia and 
VF commonly occurs during the early 
minutes after return of cardiac activity. 
Episodes of VF have been reported 
to occur in up to 79% of patients, with 
the number of episodes inversely cor-
related with ultimate survival. (26) The 
mechanisms responsible for postresus-
citation arrhythmias are complex but 
probably involve prominently cytosolic 
Ca2+ overload with afterdepolarizations 
triggering ventricular ectopic activity. 
(27) In addition, there are repolarization 
abnormalities that include shortening 
of the action potential (AP) duration, 
decreased AP amplitude, and develop-
ment of AP duration alternant creating 
conditions for reentry. (28) Experimen-
tally, these repolarization abnormalities 
are short-lived (5 to 10 minutes) and 
coincide with the interval of increased 
propensity for ventricular arrhythmias 
and recurrent VF. (16) We have report-
ed marked attenuation of reperfusion 
arrhythmias and prevention of episodes 
of refibrillation by NHE-1 inhibitors given 




Variable degrees of left ventricular sys-
tolic and diastolic dysfunction develop 
after resuscitation from cardiac arrest 
despite full restoration of coronary 
blood flow. Left ventricular dysfunction 
is largely reversible, consistent with 
the definition of myocardial stunning. 
(30-33)
Systolic dysfunction has been docu-
mented using load-independent indi-
ces of contractility showing decreases 
in the slope of the end-systolic pres-
sure-volume relationship, known as 
elastance, and increases in the volume 
intercept at a left ventricular pressure of 
100 mm Hg (V100). (31) Impaired con-
tractility leads to reductions on global 
indices of ventricular performance 
such as cardiac index, ejection frac-
tion, and left ventricular stroke work 
(32,34,35) and renders the heart sus-
ceptible to afterload increases during 
the postresuscitation phase. In a pig 
model of VF and closed chest resusci-
tation, the administration of vasopres-
sin during cardiac resuscitation was 
associated with decreased left ven-
tricular performance with reversal by 
administration of a specific antagonist 
of the V1 receptor. (36)
Diastolic dysfunction is characterized 
by left ventricular wall thickening with 
reductions in end-diastolic volume and 
impaired relaxation, (16) and appears 
to be maximal immediately after resto-
ration of spontaneous circulation. The 
magnitude of diastolic dysfunction cor-
relates closely with the magnitude of 
ischemic contracture, (37) suggesting 
a common pathogenic thread with dia-
stolic dysfunction being a manifestation 
of resolving ischemic contracture. From 
a functional perspective, diastolic dys-
function may limit the compensatory 
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ventricular dilatation required to over-
come decreased contractility accord-
ing to the Frank-Starling mechanism.
Effects of cardiac arrest 
and resuscitation on 
cardiac mitochondria
The underlying mechanism of cell 
injury during ischemia and reperfusion 
is complex and time-sensitive. Some 
processes develop coincident with the 
onset of ischemia and during reperfu-
sion leading to abnormalities in energy 
metabolism, acid base status, and 
intracellular ion homeostasis. Other 
processes develop later and encom-
pass activation of various signaling 
pathways that have deleterious or ben-
eficial effects on specific effectors, but 
associated with sustained disruption of 
energy production, contractile dysfunc-
tion, and activation of apoptotic path-
ways. Discussion on the various cell 
mechanisms responsible for cell injury 
is beyond the scope of this review. 
However, pertinent to our discussion 
is the mounting evidence pointing to 
mitochondria as key target organelles 
of reperfusion injury. (38-47)
Energy production
The mitochondria are organelles pres-
ent in all eukaryotic cells and respon-
sible for production of more than 90% 
of the ATP requirements. Mitochondria 
have an inner membrane that is highly 
impermeable and folds inwardly into 
the mitochondrial matrix forming mul-
tiple cristae where proteins responsible 
for oxidative phosphorylation reside. 
The outer mitochondrial membrane is 
more permeable given the abundance 
of channel-forming proteins, such as 
the voltage dependent anion chan-
nel (VDAC). Generation of ATP results 
from oxidation of NADH in the elec-
tron transport chain. This chain is com-
posed of protein complexes assembled 
along the inner mitochondrial mem-
brane where electrons are transferred 
down their redox potential while H+ are 
pumped into the intermembrane space. 
The accumulation of H+ in the inter-
membrane space establishes along 
with its voltage gradient (negative in 
the matrix side) a protonmotive force 
which is used by FoF1 ATP synthase 
to form ATP from ADP and inorganic 
phosphate.
Mitochondrial ATP is used to phosphor-
ylates creatine, forming creatine phos-
phate which is then shuttled outside 
mitochondria to key sites where ATP 
is utilized to support contractile activity 
(acto-myosin ATPase), Ca2+ reuptake 
(sarcoplasmic reticulum Ca2+ ATPase), 
and resting membrane potential (sarco-
lemmal Na+-K+ ATPase). (48,49) Cre-
atine phosphate rephosphorylates ADP, 
ensuring that adequate free energy for 
ATP hydrolysis is available at these 
reaction sites. (48) Dephosphorylated 
creatine is shuttled back to mitochon-
dria for rephosphorylation closing the 
phosphotransfer circuit. (50,51)
Disruption of the inner membrane per-
meability leads to collapse of the H+ 
gradient compromising the protonmo-
tive force required for ATP synthesis. 
One important mechanism of disrup-
tion of the inner membrane permeability 
at the time of reperfusion is opening of 
the mitochondrial permeability transi-
tion pore (mPTP). The mPTP is a high-
conductance mega channel formed by 
apposition of transmembrane proteins 
from the inner and the outer mitochon-
drial membrane. (40) Opening of the 
pore − in addition to causing collapse 
of the inner membrane voltage and 
uncoupling oxidative phosphorylation 
− allows molecules up to 1.5 kDa to 
enter the mitochondrial matrix along 
with water and solutes. This leads to 
mitochondrial swelling with stretching 
and disruption of the outer mitochon-
drial membrane. (40) Factors present 
at the time of reperfusion and respon-
sible for mPTP opening include Ca2+ 
overload, production of reactive oxygen 
species, depletion of ATP and ADP, 
and increased inorganic phosphate. 
(40) Intracellular acidosis at the time of 
reperfusion appears to prevent mPTP 
opening.
Apoptotic signaling
In addition to the key role on energy 
production, mitochondria can also sig-
nal cell death by activation of the intrin-
sic apoptotic pathway through release 
of cytochrome c. Cytochrome c is a 
14 kDa hemoprotein normally present 
in the intermembrane mitochondrial 
space that plays a key role transfer-
ring electrons from complex III to com-
plex IV. However, cytochrome c can 
be released to the cytosol prompting 
the formation of an oligomeric complex 
with dATP and the apoptotic protease 
activating factor-1 (Apaf-1). (38) This 
complex recruits procaspase-9 forming 
the so-called apoptosome. In the apop-
tosome, procaspase-9 is activated and 
then released as caspase-9, which in 
turn, activates the executioner caspas-
es 3, 6, and 7. (52,53) Active execution-
er caspases cleave several cytoplas-
mic proteins including α-spectrin and 
actin and nuclear proteins including 
poly (ADP-ribose) polymerase (PARP), 
lamin A, and the inhibitor of caspase 
activated DNase (ICAD). Cleavage of 
ICAD leads to activation of caspase 
activated DNase (CAD) which in turn 
cleaves chromatin into 180 to 200 bp 
fragments. Other substrates activated 
during apoptosis include components 
of DNA repair machinery and a num-
ber of protein kinases, (52) ultimately 
culminating in cell death. However, 
activation of apoptotic cascades does 
not necessarily end in cell death. We 
have recently reported activation of 
caspase-3 without evidence of DNA 
fragmentation. Other investigators have 
coined the term “apoptosis interrup-
tus” (54) to indicate the same concept. 
In myocytes, apoptosis interruptus is 
associated with disruption of contractile 
proteins, (55) suggesting that it could 
represent and adaptive response to 
lower metabolic needs under condi-
tions of metabolic stress.
Several mechanisms may explain cyto-
chrome c release. One involves mPTP 
opening causing matrix swelling and 
disruption of the outer mitochondrial 
membrane. However, cytochrome c 
can also be released without mPTP 
opening through formation of pores 
in the outer mitochondrial membrane. 
This mechanism is best explained by 
permeabilization of the outer membrane 
by pro-apoptotic proteins such as Bcl-
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2–associated X protein (Bax), Bcl-2 
homologous antagonist killer (Bak), 
or truncated BH3 interacting domain 
death agonist (Bid). (56) Anti-apoptotic 
proteins such as Bcl-2, Bcl-x, and Bcl-
w, however, may play important roles by 
counterbalancing the aforementioned 
pro-apoptotic effects. (57)
We investigated in a rat model of ven-
tricular fibrillation (VF) and closed-
chest resuscitation the effects of 
ischemia and reperfusion on cytosolic 
and systemic release of cytochrome 
c. (58) We found that cytochrome c 
is released to the cytosol after resus-
citation from VF in association with 
activation of caspase-3 and marked 
reduction in left ventricular function. 
We then measured changes in plasma 
cytochrome c in 12 rats successfully 
resuscitated after 8 minutes of untreat-
ed VF and 8 minutes of closed-chest 
resuscitation. In 3 rats that survived, 
plasma cytochrome c increased and 
decreased gradually within a 96 hour 
interval to levels not exceeding 2 μg/ml. 
In 9 rats, which died between 1.3 and 
32.5 hours post-resuscitation, plasma 
cytochrome c increased faster (0.7 ± 
0.5 vs 0.1 ± 0.05 μg/ml/hr; p = 0.046) 
and reached higher levels (4.6 ± 2.0 
vs 1.6 ± 0.3 μg/ml; p = 0.029) than 
in survivor rats. Plasma cytochrome c 
increased despite reversal of whole-
body ischemia, which was document-
ed by declining blood lactate levels in 
both survivor and non-survivor rats.
Increased plasma levels of cytochrome 
c, inversely related to outcomes, have 
also been reported in patients present-
ing with the systemic inflammatory 
response syndrome, (59) influenza-
associated encephalopathy, (60) and 
fulminant hepatitis. (61) Accordingly, 
release of cytochrome c to the blood-
stream may serve to identify mitochon-
drial injury, quantitate its severity, and 
predict survival. Future work is planned 
to assess the effects of interventions 
targeting mechanisms of mitochondri-
al injury during reperfusion, anticipat-
ing preservation of organ function and 
improved survival in relation to inter-
ventions that (i) ameliorate mitochon-
drial Ca2+ overload and (ii) reduce 
the sensitivity of the mPTP. Ameliora-
tion of mitochondrial Ca2+ overload 
can be accomplished by inhibition of 
the sodium-hydrogen exchanger iso-
form-1 using cariporide (16,29) and 
by inhibition of the mitochondrial Ca2+ 
uniporter using Ru360. (62) The sen-
sitivity of mPTP can be reduced by 
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